HGS To Focus On “Core Pipeline” As Part Of Cost-Cutting; CEO Steps Down
Executive Summary
Human Genome Sciences is implementing a cost reduction program to focus its resources on clinical development of its immunology/infectious disease and oncology drug candidates
You may also be interested in...
R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO
Drug companies should consider outsourcing R&D work to other countries in light of cost pressures in the U.S., Human Genome Sciences CEO William Haseltine, PhD, said
R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO
Drug companies should consider outsourcing R&D work to other countries in light of cost pressures in the U.S., Human Genome Sciences CEO William Haseltine, PhD, said
Second Continuous Marketing Application Pilot Program Is 44% Enrolled
Enrollment in FDA's second continuous marketing application pilot program is nearly 50% enrolled